The present invention relates to a method for recovering bismuth (Bi) from a solid impurity stream generated during the pyrometallurgical production of copper, wherein the method comprises the steps of leaching the solid impurity stream in an acid medium at a pH under 0.5 to obtain a Bi-rich leachate; and titrating the Bi-rich leachate at a pH between 1.0 and 3.5 by using a strong base to obtain a precipitate of bismoclite (BiOCI). In a related aspect, the invention also relates to a method for the recovery of valuable materials and for the safe disposal of toxic contaminants from a solid impurity stream generated during the pyrometallurgical production of copper.
1234567-207-20 (SEQ ID No1): wherein Xaa can be any amino acid for use in the treatment and/or prevention of Retinitis Pigmentosa and a pharmaceutical composition comprising one or more synthetic peptide analog from PIF peptides and one or more acceptable carriers.
The present disclosure provides a compound of formula I, as well as complexes and compositions comprising a compound of formula I, wherein said compositions and complexes are useful for delivery of certain agents, including, for example, nucleic acids.
C07H 15/14 - Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07H 99/00 - Subject matter not provided for in other groups of this subclass
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 1/00 - Processes for the preparation of sugar derivatives
The present disclosure provides complexes comprising: i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from: a sterol, a helper lipid, an immunomodulator, and a targeting molecule; and uses thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07H 15/14 - Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
The present disclosure provides complexes comprising a cationic oligosaccharide and an RNA, wherein the cationic oligosaccharide comprises a plurality of cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6, and a ratio of N/P in the complex is less than 20:1
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07H 15/14 - Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07H 99/00 - Subject matter not provided for in other groups of this subclass
C07H 1/00 - Processes for the preparation of sugar derivatives
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The invention relates to new tri-substituted tetrahydrofurans of formula (I) and their use as antiviral agent in the treatment and/or prevention of coronavirus infections and more particularly SARS-CoV-2 infection.
GENETIC CASSETTE COMPRISING THE PHT PATHWAY GENES, RECOMBINANT HOST CELLS COMPRISING IT AND THEIR USE IN THE DEGRADATION AND VALORIZATION OF PHTHALATES
The present invention provides a recombinant genetic cassette which comprises the catabolic genes involved in the pht pathway as well as an SBP-dependent secondary transporter that are essential for microbial phthalate degradation. The invention also relates to recombinant host cells comprising this cassette and are useful for the aerobic or anaerobic biodegradation of phthalates, preferably o-phthalate (PAs), and for the bioconversion of PAs towards the biosynthesis of value-added biodegradable polymers, such as polyhydroxyalkanoates (PHAs), preferably polyhydroxybutyrates (PHBs).
H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances
The invention relates to an improved miniature device that has been developed for use with liquids at high pressures and at a controlled temperature for the extraction of different types of chemical species from semi-solid or solid samples contained in a closed cell, thereby overcoming certain limitations linked to the thermal inertia of the system. The device includes a resistor that is inserted into a steel tube and a motor which guides air through the tube in order to heat the chamber containing the extraction cells. Both the resistors and the motor can switch on and off independently. The improved device reduces the time required for the liquid-based extraction of different types of chemical species from semi-solid or solid samples, thereby providing a very beneficial advance in terms of solving different problems that exist within the field of sample preparation in analytical chemistry.
The invention relates to an apparatus for the analysis and quantification of the analyte concentration in a sample, using external magnetoresistive sensors, comprising: a mechanical system (1), a magnetoresistive sensor (3), and magnetisation means (21 and 22). According to the invention, the mechanical system (1) includes means ensuring that the substrate (4) and the sensor (3) are disposed at the smallest distance possible from one another, so as to obtain a better reading, and the magnetisation means (21 and 22) can take the form of external coils (21), a permanent magnet (22) or a combination of both.
The invention relates to a polarisation converter and to a focusing device based on said converter, of the type comprising an ADTN cell which converts the linear polarisation of an incident light beam that fulfills the Mauguin condition to radial polarisation with two halves that are half-wave phase-displaced along a discontinuity or disclination, associated with a half wave compensator element which acts differently in relation to the two halves of the beam defined by the disclination in order to produce a phase- and radially-polarised beam. The compensator element consists of one or two solid bodies through which the beam can pass, which are applied to one or both halves of the light beam defined by the disclination and which introduce a relative half-wave phase displacement between the electric fields of the two halves in relation to the input thereof.
The invention relates to an achromatic polarisation converter and to a focusing device based on said converter, of the type comprising an ADTN cell which converts the linear polarisation of an incident light beam that fulfills the Mauguin condition to radial polarisation with two halves that are half-wave phase-displaced along a disclination, associated with a half wave compensator element which acts differently in relation to the two halves of the beam defined by the disclination in order to produce a phase- and radially-polarised beam. The compensator element consists of at least one passive liquid crystal cell formed by plane-parallel plates coated with a layer of material that orients the liquid crystal in directions such that, in co-operation with the formation of the liquid crystals, the director is forced to rotate in both halves of the beam, said rotations differing by a half-spiral, thereby preventing the phase displacement of the two halves without the application of external fields.
The present invention relates to the production of transgenic plants with altered levels of starch as a result of the variation of the activity of vegetable nudix that hydrolyse ADP-glucose. Therefore, a description is given in this invention of how to obtain not only transgenic plants that over-express vegetable ASPPs and therefore accumulate little starch, but also transgenic plants that have a high starch content as a result of the reduction of the vegetable ASPP activity.
The invention relates to a novel fructofuranosidase activity for obtaining the prebiotic oligosaccharide 6-kestose. One aspect of the invention characterises a novel transfructosilase activity which is associated with the extracellular invertase of Schwanniomyces occidentalis (specifically the strains selected from the group comprising ATCC260077, ATCC7410 and ATCC20499) and which can be used to obtain prebiotic oligosaccharides, mainly 6-kestose, which are widely used in the food industry. Another aspect of the invention relates to the method for obtaining an enzymatic product as well as to the substantially-pure enzyme with fructofuranosidase activity.
FUNDACIONES CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES (Spain)
Inventor
Redondo Moya, Juan Miguel
Rodríguez Márquez, Antonio
Martínez Martínez, Sara
Abstract
The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides LxVPc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (CN) - NFAT and of the phosphate activity of CN. Said compounds are useful immunosuppressors and serve as a base for the preparation of therapeutic compositions for the prophylactics and treatment of human diseases associated with T-lymphocyte activation, including, but not limited to, autoimmune diseases, inflammation and allergy or transplant rejections. In addition, said peptides and the associated biological and genetic material can form useful tools for the development of tests that can be used to find compounds that have a selective antagonist activity in relation to CN.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
patents